Patient characteristics with systemic treatment
| . | Classic n = 1245 . | Late n = 193 . | P value . |
|---|---|---|---|
| Median age at HCT, y (range) | 58 (18-79) | 61 (19-78) | < .001 |
| Recipient age, category | |||
| <55 | 392 (31.5) | 33 (17.1) | < .001 |
| ≥55 | 853 (68.5) | 160 (82.9) | |
| Sex mismatch | |||
| Other | 1057 (84.9) | 145 (75.1) | .001 |
| Female-to-male | 188 (15.1) | 48 (24.9) | |
| Primary disease | |||
| Acute leukemia | 653 (52.4) | 100 (51.8) | .475 |
| MDS/MPN | 349 (28.0) | 63 (32.6) | |
| Malignant lymphoma | 103 (8.3) | 12 (6.2) | |
| Other | 140 (11.2) | 18 (9.3) | |
| Disease risk | |||
| Standard | 991 (79.6) | 165 (85.5) | .064 |
| High | 254 (20.4) | 28 (14.5) | |
| Donor type | |||
| HLA-MRD | 256 (20.6) | 86 (44.6) | <.001 |
| HLA-MUD | 708 (56.9) | 88 (45.6) | |
| HLA-MMUD | 131 (10.5) | 8 (4.1) | |
| Haploidentical donor | 150 (12.0) | 11 (5.7) | |
| GVHD prophylaxis | |||
| CNI/MTX based | 649 (52.1) | 135 (69.9) | <.001 |
| CNI/MMF based | 290 (23.3) | 37 (19.2) | |
| PTCy | 248 (19.9) | 13 (6.7) | |
| Other | 58 (4.7) | 8 (4.1) | |
| HCT-CI | |||
| 0-2 | 814 (65.4) | 120 (62.2) | .418 |
| ≥3 | 431 (34.6) | 73 (37.8) | |
| In vivo T-cell depletion | |||
| No | 760 (61.0) | 149 (77.2) | <.001 |
| Yes | 485 (39.0) | 44 (22.8) | |
| Donor source | |||
| Bone marrow | 211 (16.9) | 19 (9.8) | .011 |
| Peripheral blood | 1034 (83.1) | 174 (90.2) | |
| Conditioning | |||
| MAC (TBI < 8 Gy) | 516 (41.4) | 51 (26.4) | <.001 |
| MAC (TBI ≥ 8 Gy) | 179 (14.4) | 15 (7.8) | |
| RIC | 550 (44.2) | 127 (65.8) | |
| CNI discontinuation by day 100 | |||
| Discontinued | 13 (6.7) | NA | |
| Continued | 180 (93.3) | ||
| Median year of HCT (range) | 2017 (2014-2021) | 2018 (2014-2021) | .120 |
| . | Classic n = 1245 . | Late n = 193 . | P value . |
|---|---|---|---|
| Median age at HCT, y (range) | 58 (18-79) | 61 (19-78) | < .001 |
| Recipient age, category | |||
| <55 | 392 (31.5) | 33 (17.1) | < .001 |
| ≥55 | 853 (68.5) | 160 (82.9) | |
| Sex mismatch | |||
| Other | 1057 (84.9) | 145 (75.1) | .001 |
| Female-to-male | 188 (15.1) | 48 (24.9) | |
| Primary disease | |||
| Acute leukemia | 653 (52.4) | 100 (51.8) | .475 |
| MDS/MPN | 349 (28.0) | 63 (32.6) | |
| Malignant lymphoma | 103 (8.3) | 12 (6.2) | |
| Other | 140 (11.2) | 18 (9.3) | |
| Disease risk | |||
| Standard | 991 (79.6) | 165 (85.5) | .064 |
| High | 254 (20.4) | 28 (14.5) | |
| Donor type | |||
| HLA-MRD | 256 (20.6) | 86 (44.6) | <.001 |
| HLA-MUD | 708 (56.9) | 88 (45.6) | |
| HLA-MMUD | 131 (10.5) | 8 (4.1) | |
| Haploidentical donor | 150 (12.0) | 11 (5.7) | |
| GVHD prophylaxis | |||
| CNI/MTX based | 649 (52.1) | 135 (69.9) | <.001 |
| CNI/MMF based | 290 (23.3) | 37 (19.2) | |
| PTCy | 248 (19.9) | 13 (6.7) | |
| Other | 58 (4.7) | 8 (4.1) | |
| HCT-CI | |||
| 0-2 | 814 (65.4) | 120 (62.2) | .418 |
| ≥3 | 431 (34.6) | 73 (37.8) | |
| In vivo T-cell depletion | |||
| No | 760 (61.0) | 149 (77.2) | <.001 |
| Yes | 485 (39.0) | 44 (22.8) | |
| Donor source | |||
| Bone marrow | 211 (16.9) | 19 (9.8) | .011 |
| Peripheral blood | 1034 (83.1) | 174 (90.2) | |
| Conditioning | |||
| MAC (TBI < 8 Gy) | 516 (41.4) | 51 (26.4) | <.001 |
| MAC (TBI ≥ 8 Gy) | 179 (14.4) | 15 (7.8) | |
| RIC | 550 (44.2) | 127 (65.8) | |
| CNI discontinuation by day 100 | |||
| Discontinued | 13 (6.7) | NA | |
| Continued | 180 (93.3) | ||
| Median year of HCT (range) | 2017 (2014-2021) | 2018 (2014-2021) | .120 |
HCT-CI, HCT-specific comorbidity index; MDS/MPN, myelodysplastic syndromes/myeloproliferative neoplasms; MMF, mycophenolate mofetil; MTX, methotrexate; TBI, total body irradiation.